---
title: "Weight Watchers Q2 2026 Earnings: Clinical Growth Could Not Offset Behavioral Decline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295019223.md"
description: "Weight Watchers reported Q2 2026 revenue of $162.3 million, a 14.2% decline year-over-year, driven by a 22.7% drop in Behavioral subscription revenue that offset 30.4% growth in Clinical subscriptions. Diluted EPS was $1.41, though comparable historical data is limited due to fresh start accounting following its 2025 reorganization. Adjusted EBITDA reached $39.8 million, and the company reaffirmed its full-year guidance."
datetime: "2026-08-05T21:28:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295019223.md)
  - [en](https://longbridge.com/en/news/295019223.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295019223.md)
generator: "portal-rs"
---

# Weight Watchers Q2 2026 Earnings: Clinical Growth Could Not Offset Behavioral Decline

Weight Watchers (Nasdaq: WW) reported Q2 2026 revenue of $162.3 million, down 14.2% year over year, and diluted EPS of $1.41; a meaningful year-over-year EPS comparison is unavailable because of fresh start accounting following the company’s 2025 financial reorganization. Clinical growth and a favorable subscription mix lifted total ARPU, but the contraction in Behavioral subscribers continued to weigh on consolidated revenue.

## Core Financial Results

Revenue declined as the 22.7% drop in Behavioral subscription revenue more than offset 30.4% growth in Clinical subscription revenue. Adjusted EBITDA reached $39.8 million, while GAAP net income included an $11.2 million income tax benefit and a $4.6 million gain on extinguishment of debt.

Weight Watchers emerged from its financial reorganization on June 24, 2025 and subsequently adopted fresh start accounting. The company provided a combined prior-year revenue figure because fresh start adjustments did not affect revenue, but most other GAAP measures are not directly comparable.

| Metric                    | Q2 2026                | Q2 2025                  | YoY change |
| ------------------------- | ---------------------- | ------------------------ | ---------- |
| Revenue                   | $162.3 million         | $189.2 million, combined | -14.2%     |
| Gross profit / margin     | $114.1 million / 70.3% | Not comparable           | —          |
| Operating income / margin | $9.5 million / 5.8%    | Not comparable           | —          |
| Net income / margin       | $14.1 million / 8.7%   | Not comparable           | —          |
| Diluted EPS               | $1.41                  | Not comparable           | —          |
| Adjusted EBITDA / margin  | $39.8 million / 24.5%  | Not comparable           | —          |
| Operating cash flow       | $24.3 million          | Not provided             | —          |

The adjusted gross margin was 73.6%, above the GAAP gross margin because the non-GAAP measure excludes specified items, including depreciation and amortization. The company said the adjusted margin remained near record levels.

## Business and Segment Performance

The quarter showed a sharp divergence between Weight Watchers’ Behavioral and Clinical offerings. Clinical subscriber growth remained substantial, while the larger Behavioral subscriber base continued to contract. Core+, the company’s higher-value Behavioral tier, was an exception, recording its third consecutive quarter of sequential subscriber growth.

| Operating metric                     | Q2 2026        | Q2 2025        | YoY change |
| ------------------------------------ | -------------- | -------------- | ---------- |
| Behavioral subscription revenue      | $121.5 million | $157.3 million | -22.7%     |
| Clinical subscription revenue        | $39.9 million  | $30.6 million  | +30.4%     |
| Total end-of-period subscribers      | 2.489 million  | 3.167 million  | -21.4%     |
| Behavioral end-of-period subscribers | 2.291 million  | 3.040 million  | -24.6%     |
| Clinical end-of-period subscribers   | 197,000        | 127,000        | +55.7%     |
| Core+ end-of-period subscribers      | 541,000        | Not provided   | +13.9%     |
| Total monthly subscription ARPU      | $20.90         | $18.97         | +10.2%     |
| Clinical monthly subscription ARPU   | $67.55         | $78.00         | -13.4%     |

Clinical revenue grew more slowly than its subscriber count because Clinical ARPU declined. The company was also comparing against significant prior-year growth related to its former compounded semaglutide offering. Clinical subscribers were flat sequentially from Q1 after management reduced marketing investment following elevated peak-season spending.

Total subscription ARPU nevertheless increased because Clinical subscribers represented a larger share of the overall mix. That improvement helped moderate, but did not eliminate, the revenue effect of the lower total subscriber count.

## Profitability, Cash Flow, and the Balance Sheet

Marketing expense was $47.9 million, or 29.5% of revenue, compared with $92.9 million in Q1 2026. Management attributed the sequential reduction to the end of peak season and a rebalancing of investment between business lines. The lower quarterly marketing burden supported positive operating cash flow, although it coincided with flat sequential Clinical subscribers.

Weight Watchers ended June with $101.5 million in cash and cash equivalents, down from $160.3 million at the end of 2025. For the first six months of 2026, operations used $9.3 million of cash, capitalized software and website development required $11.9 million, and long-term debt payments totaled $36.8 million. The positive $24.3 million of Q2 operating cash flow therefore marked an improvement from the first quarter’s cash consumption.

During Q2, the company used $36.8 million of cash to reduce term-loan principal by $41.4 million, including a voluntary prepayment completed at 68.5% of par. These actions reduced annualized interest expense by approximately $4 million. Long-term debt, net, declined to $424.0 million from $465.5 million at year-end, but the term loan still carried a 10.53% interest rate as of June 30.

## 2026 Guidance

Management reaffirmed its previously issued full-year guidance rather than raising or lowering the ranges. The unchanged outlook indicates that the company continues to base its plan on further progress in Clinical and Core+ while managing the broader Behavioral decline and marketing spending.

| Metric          | Latest 2026 guidance      | Previous guidance         | Change     |
| --------------- | ------------------------- | ------------------------- | ---------- |
| Revenue         | $620 million-$635 million | $620 million-$635 million | Reaffirmed |
| Adjusted EBITDA | $105 million-$115 million | $105 million-$115 million | Reaffirmed |

## Risks Investors Need to Watch

-   **Behavioral contraction remains the main revenue pressure.** Behavioral subscription revenue fell 22.7%, and end-of-period Behavioral subscribers declined 24.6%. Because Behavioral remains the larger business, continued contraction could offset further Clinical growth.
-   **Clinical subscriber growth is not translating proportionally into revenue.** Clinical subscribers increased 55.7%, but Clinical revenue rose 30.4% as Clinical ARPU declined 13.4%. The economics of future Clinical growth will therefore be as important as subscriber additions.
-   **Marketing efficiency involves a growth trade-off.** Marketing expense fell sharply from Q1, supporting cash generation, but Clinical subscribers were flat sequentially after the company recalibrated spending.
-   **Debt remains costly despite the Q2 reduction.** The company lowered principal and future interest expense, but net long-term debt remained $424.0 million and the term loan rate was 10.53% at quarter-end.
-   **Fresh start accounting limits historical comparisons.** Revenue can be compared using the company’s combined prior-year presentation, but many GAAP profit and EPS comparisons are distorted by the 2025 reorganization and accounting reset.

## Summary

Weight Watchers’ Q2 2026 results showed progress in Clinical, Core+, ARPU, and quarterly cash generation, but those gains did not offset the continued decline in the broader Behavioral subscriber base. The company also reduced debt and reaffirmed its full-year outlook. The main issues to monitor are whether Clinical and Core+ can sustain growth with lower marketing investment, whether Clinical ARPU stabilizes, and whether positive operating cash flow continues while the company services its remaining debt.

Find out more

### Related Stocks

- [WGHTQ.US](https://longbridge.com/en/quote/WGHTQ.US.md)
- [WW.US](https://longbridge.com/en/quote/WW.US.md)

## Related News & Research

- [WW International Insider Makes Bold Six-Figure Stock Move](https://longbridge.com/en/news/296568937.md)
- [WW International director Nikolaj H. Sjoqvist acquires 7,235 common shares worth $100,102.4](https://longbridge.com/en/news/296530419.md)
- [Morgan Stanley Gives a Hold Rating to WW Grainger (GWW)](https://longbridge.com/en/news/296788730.md)
- [Gosol Energy corrects 2025 balance sheet comparatives; 2026 figures unchanged](https://longbridge.com/en/news/297176578.md)
- [Revenio Group to publish half-year report for January-June 2026](https://longbridge.com/en/news/297131129.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**